[go: up one dir, main page]

ES2177316T3 - Anticuerpos humanos antifacotores ix/ixa. - Google Patents

Anticuerpos humanos antifacotores ix/ixa.

Info

Publication number
ES2177316T3
ES2177316T3 ES99943928T ES99943928T ES2177316T3 ES 2177316 T3 ES2177316 T3 ES 2177316T3 ES 99943928 T ES99943928 T ES 99943928T ES 99943928 T ES99943928 T ES 99943928T ES 2177316 T3 ES2177316 T3 ES 2177316T3
Authority
ES
Spain
Prior art keywords
ixa
fix
human antibodies
antifacotor
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99943928T
Other languages
English (en)
Inventor
Camellia W Adams
Brigitte Devaux
Dan L Eaton
Philip E Hass
J Kevin Judice
Daniel Kirchhofer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2177316T3 publication Critical patent/ES2177316T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere al aislamiento, identificación, síntesis, expresión y purificación de anticuerpos que reaccionan con el factor IX (FIX)/factor IXa (FIXa), y especialmente con el dominio Gla de FIX/FIXa. En aspectos particulares, la invención proporciona anticuerpos humanos que reaccionan con el dominio Gla de FIX/FIXa humano. La invención se refiere además a composiciones, especialmente composiciones farmacéuticas, artículos de fabricación, y procedimientos para inhibir la actividad del FIX/FIXa, e inhibir la coagulación dependiente del FIX/FIXa.
ES99943928T 1998-08-28 1999-08-26 Anticuerpos humanos antifacotores ix/ixa. Expired - Lifetime ES2177316T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9823398P 1998-08-28 1998-08-28
US12276799P 1999-03-03 1999-03-03

Publications (1)

Publication Number Publication Date
ES2177316T3 true ES2177316T3 (es) 2002-12-01

Family

ID=26794469

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99943928T Expired - Lifetime ES2177316T3 (es) 1998-08-28 1999-08-26 Anticuerpos humanos antifacotores ix/ixa.

Country Status (15)

Country Link
US (3) US6624295B1 (es)
EP (1) EP1107996B1 (es)
JP (1) JP4638035B2 (es)
CN (1) CN1183160C (es)
AT (1) ATE217889T1 (es)
AU (1) AU766551C (es)
BR (1) BR9913435A (es)
CA (1) CA2341276C (es)
DE (1) DE69901569T2 (es)
DK (1) DK1107996T3 (es)
ES (1) ES2177316T3 (es)
IL (1) IL140917A0 (es)
NZ (1) NZ509430A (es)
PT (1) PT1107996E (es)
WO (1) WO2000012562A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE0000675D0 (sv) * 2000-03-02 2000-03-02 Protease Ab Monoclonal antibodies
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
ATE345816T1 (de) * 2000-05-15 2006-12-15 Smithkline Beecham Corp Antithrombose agenzien
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en) * 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
DK1905839T4 (da) * 2006-09-22 2019-10-07 Wacker Chemie Ag Fremgangsmåde til fermentativ fremstilling af proteiner
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
AU2011234532B2 (en) 2010-03-30 2015-04-09 Octapharma Ag Process for the purification of a Growth Factor Protein
DK3133157T3 (da) * 2010-03-30 2019-08-12 Octapharma Ag Fremgangsmåde til oprensning af vitamin k-afhængige proteiner
WO2011130324A1 (en) * 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
CA2834432C (en) * 2011-05-23 2020-01-07 Sekisui Medical Co., Ltd. Method of inhibiting nonspecific reaction in pivka-ii assay reagent
TWI617319B (zh) * 2015-09-01 2018-03-11 免疫功坊股份有限公司 用以治療病理性血栓的融合蛋白
EP3558370A2 (en) * 2016-12-23 2019-10-30 Novartis AG Methods of treatment with anti-factor xi/xia antibodies
US12084512B2 (en) 2017-02-01 2024-09-10 Novo Nordisk A/S Procoagulant antibodies
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体
CN116333145B (zh) * 2023-04-14 2023-11-07 北京基科晟斯医药科技有限公司 结合活化凝血因子ix的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720983A1 (de) * 1987-06-25 1989-01-05 Hoechst Ag Immunometrisches bestimmungsverfahren
AU7766391A (en) 1990-04-23 1991-11-11 Corvas International N.V. Thrombus-specific antibody derivatives
ATE204299T1 (de) 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
JPH08510922A (ja) 1994-03-17 1996-11-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ＥＧＦＲ一本鎖Ｆｖおよび抗ＥＧＦＲ抗体
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
US20060088534A1 (en) 2006-04-27
AU766551C (en) 2005-02-17
NZ509430A (en) 2002-04-26
WO2000012562A1 (en) 2000-03-09
US6624295B1 (en) 2003-09-23
EP1107996A1 (en) 2001-06-20
US20060193851A1 (en) 2006-08-31
AU5692399A (en) 2000-03-21
ATE217889T1 (de) 2002-06-15
DK1107996T3 (da) 2002-09-16
DE69901569D1 (de) 2002-06-27
CA2341276C (en) 2005-10-11
BR9913435A (pt) 2001-09-25
JP4638035B2 (ja) 2011-02-23
IL140917A0 (en) 2002-02-10
AU766551B2 (en) 2003-10-16
US7049411B2 (en) 2006-05-23
DE69901569T2 (de) 2002-12-19
CN1317015A (zh) 2001-10-10
CA2341276A1 (en) 2000-03-09
PT1107996E (pt) 2002-10-31
US7354585B2 (en) 2008-04-08
CN1183160C (zh) 2005-01-05
JP2002523081A (ja) 2002-07-30
EP1107996B1 (en) 2002-05-22

Similar Documents

Publication Publication Date Title
ES2177316T3 (es) Anticuerpos humanos antifacotores ix/ixa.
ATE304358T1 (de) (s,s)-reboxetin zur behandlung von migränekopfschmerzen
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
MEP8209A (en) Modified factor viii
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
ATE376026T1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
NO20061736L (no) Krystallform av epotilon B
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
CY1109984T1 (el) Παραλλαγες gla πεδιου παραγοντα vii ή viia
DK1200418T3 (da) Nematodicide trifluorbutener
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
SE9802729D0 (sv) Novel Compounds
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
SE9802937D0 (sv) Novel compounds
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
ATE386525T1 (de) 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri